# A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Source: https://onco.cc/trials/nct04606771/  
OnCo record `nct04606771` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Osimertinib, Savolitinib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC is a phase 2 interventional study registered as NCT04606771 by AstraZeneca, with 30 participants enrolled, started 2020-09-28 and due to reach its primary completion in 2022-12-21. Interventions recorded: Osimertinib + Savolitinib, Savolitinib + Placebo. Conditions listed: Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT04606771
- Phase: 2
- Setting: A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination With Osimertinib vs Savolitinib in Combination With Placebo in Patients With EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib
- Sponsor: AstraZeneca
- Enrolled: 30
- Outcomes: Objective Response Rate (ORR): Savolitinib Plus Osimertinib 57.1% vs Savolitinib Plus Placebo 12.5%; Overall Survival (OS): Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo 13.37 months; Progression-free Survival (PFS): Savolitinib Plus Osimertinib 7.36 months vs Savolitinib Plus Placebo 1.64 months

## Sources

- ClinicalTrials.gov NCT04606771: https://clinicaltrials.gov/study/NCT04606771

## Connected records

- cancers: [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/), [Savolitinib](https://onco.cc/drugs/savolitinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04606771.json